A “life changing” new therapy for an extremely rare medical condition which causes patients to grow a second skeleton has been proven successful in a key clinical trial. Relatives of people living with fibrodysplasia ossificans progressiva (FOP) say that they have “desperately waited” years for a medicine to “stop the disease ... A “life changing” new therapy for an extremely rare medical condition which causes patients to grow a second skeleton has been proven successful in a key clinical trial. Relatives of people living with fibrodysplasia ossificans progressiva (FOP) say that they have “desperately waited” years for a medicine to “stop the disease in its tracks”. Patients grow extra bones where they don’t belong, including within muscles and tendons A multi-country clinical trial has returned positive results for those with fibrodysplasia ossificans progressiva (Getty Images/iStockphoto) However, the new “disease-modifying” treatment has now been shown to cut new bone growth by over 90 per cent, decrease flare-ups and potentially provide renewed hope for surgical options in the future. FOP ranks among the world's rarest medical conditions, impacting just one in every million people. Because the disease is so rare, the clinical trial took place in 16 countries and regions, including the UK.

Original title: “Major breakthrough in treatment for ultra-rare 'second skeleton' disease fibrodysplasia ossificans progressiva | The Independent”

The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regeneron’s recently approved Pasatru and Ipsen’s Sohonos.

Original title: “FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease”

efficacy and safety of garetosmab an activin a blocking antibody in fibrodysplasia ossificans progressiva optima a randomised double blind placebo controlled phase 3 trial

Original title: “Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.”

measures of mortality among people living with fibrodysplasia ossificans progressiva in the united states 2017 2023

Original title: “Measures of mortality among people living with fibrodysplasia ossificans progressiva in the United States, 2017-2023.”

bcx9250 is a potent small molecule inhibitor of activin a receptor type 1 acvr1 alk2 for fibrodysplasia ossificans progressiva

Original title: “BCX9250 is a potent small-molecule inhibitor of Activin A Receptor Type 1 (ACVR1/ALK2) for fibrodysplasia ossificans progressiva.”

socioeconomic impacts of fibrodysplasia ossificans progressiva evidence from a retrospective case control study in france

Original title: “The socioeconomic impacts of fibrodysplasia ossificans progressiva: evidence from a retrospective case-control study in France.”

body composition and energy expenditure of patients with fibrodysplasia ossificans progressiva

Original title: “Body composition and energy expenditure of patients with Fibrodysplasia Ossificans Progressiva.”

hyperactive bmp and mechanosignaling remodel chromatin to drive aberrant osteogenesis in fop

Original title: “Hyperactive BMP and Mechanosignaling Remodel Chromatin to Drive Aberrant Osteogenesis in FOP.”

long term noninvasive ventilation in children with fibrodysplasia ossificans progressiva

Original title: “Long-term noninvasive ventilation in children with fibrodysplasia ossificans progressiva.”

knowledge skills and attitudinal gaps in fibrodysplasia ossificans progressiva diagnosis and management in the united states

Original title: “Knowledge, skills, and attitudinal gaps in fibrodysplasia ossificans progressiva diagnosis and management in the United States.”

content validation of the flares diary a qualitative analysis of the flares experience within the fibrodysplasia ossificans progressiva fop population

Original title: “Content Validation of the Flares Diary: A Qualitative Analysis of the Flares Experience Within the Fibrodysplasia Ossificans Progressiva (FOP) Population.”

atypical clinical presentation and diagnostic difficulties of a rare disease fibrodysplasia ossificans progressiva

Original title: “Atypical Clinical Presentation and Diagnostic Difficulties of a Rare Disease: Fibrodysplasia Ossificans Progressiva.”

A Colorado family is calling for change and sharing their struggle after a clinical trial their son relied on suddenly ended. This week marks Rare Disease Week, a time when families across the country are sharing their struggles with access to treatments and clinical trials, and their hopes for change, with lawmakers and federal health officials. Colorado family pushes for change after rare disease clinical trial abruptly ends 04:23 Caleb was eventually diagnosed with fibrodysplasia ossificans progressiva, or FOP, an extremely rare genetic disorder in which muscles, connective tissues and ligaments are gradually replaced by bone. There is no cure and no FDA‑approved treatment. That hope was shaken in December when the drug's manufacturer announced it was ending the trial after failing to meet a required endpoint of reducing bone growth. "The message said, 'Speak with your physician for other options,'" Stephanie Burgess said. "For which there aren't any." Now, the Burgess family is sharing its experience not just for Caleb, but for others living with rare diseases.

Original title: “Colorado family pushes for change after rare disease clinical trial abruptly ends - CBS Colorado”

/PRNewswire/ -- Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an... Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide. The partnership will ensure sustained commercial supply for FOP therapy and broaden capabilities to handle multiple highly potent compounds at commercial scale, addressing critical needs in rare disease treatment. Marlene Leuenberger, VP and General Manager, Quotient Sciences, Philadelphia commented: "This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences' unwavering commitment to supporting patients with ultra-rare diseases.

Original title: “Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment”

Only 5% of rare diseases have treatments, but approximately half have patient advocacy organizations; these groups have the potential to play major roles in positively influencing research and development of drugs, clinical trials, and regulations by championing funding and awareness efforts, ... Only 5% of rare diseases have treatments, but approximately half have patient advocacy organizations; these groups have the potential to play major roles in positively influencing research and development of drugs, clinical trials, and regulations by championing funding and awareness efforts, forming connections between experts and drug developers, advocating for changes to regulation to expedite research, facilitating patient registries, or other initiatives. The panel was provided with a guidance document used by the Fibrodysplasia Ossificans Progressiva Association (IFOPA), which provided a foundation upon which the panel was asked to build guidelines for the entire rare disease community. Based on the panel’s input, the researchers drafted guidelines, then revised on the basis of further panel comments. A second draft was reviewed by 6 experts from advocacy organizations and industry before being finalized. The resulting document, titled “Guidelines for Interactions Between Patient Advocacy Organizations and Biopharmaceutical Companies,” comprises 4 sections, highlights of which include the following: A rare disease, by definition, affects only a small number of individuals, but together, all of the approximately 7000 known rare diseases affect an estimated 350 million patients worldwide (including approximately 30 million people in the United States). Only 5% of these diseases have treatments, but approximately half have patient advocacy organizations; these groups have the potential to play major roles in positively influencing research and development of drugs, clinical trials, and regulations by championing funding and awareness efforts, forming connections between experts and drug developers, advocating for changes to regulation to expedite research, facilitating patient registries, or other initiatives. paper in Orphanet Journal of Rare Diseases describes efforts to address unmet needs for guidelines on day-to-day decision making by rare disease patient advocacy organizations when working with biopharmaceutical companies.

Original title: “New Guidelines for Rare Disease Advocacy Groups to Navigate Interactions With Pharma | AJMC”